Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study

References

• AdeloyeDChuaSLeeCGlobal Health Epidemiology Reference GGlobal and regional estimates of COPD prevalence: systematic review and meta-analysisJ Glob Health20155202041526755942
   PubMed Web of Science ®Google Scholar
• VogelmeierCFCrinerGJMartinezFJGlobal strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summaryAm J Respir Crit Care Med2017195555758228128970
   PubMed Web of Science ®Google Scholar
• DonaldsonGCSeemungalTABhowmikAWedzichaJARelationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseaseThorax2002571084785212324669
   PubMed Web of Science ®Google Scholar
• BafadhelMMcKennaSTerrySAcute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkersAm J Respir Crit Care Med2011184666267121680942
   PubMed Web of Science ®Google Scholar
• Lopez-CamposJLAgustiAHeterogeneity of chronic obstructive pulmonary disease exacerbations: a two-axes classification proposalLancet Respir Med20153972973426165134
   PubMed Web of Science ®Google Scholar
• WedzichaJABanerjiDChapmanKRIndacaterol-glycopyrronium versus salmeterol-fluticasone for COPDN Engl J Med2016374232222223427181606
   PubMed Web of Science ®Google Scholar
• RocheNChapmanKRVogelmeierCFBlood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment. Data from the FLAME trialAm J Respir Crit Care Med201719591189119728278391
   PubMed Web of Science ®Google Scholar
• AgustiAHurdSJonesPFAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohortsEur Respir J20134251391140123645406
   PubMed Web of Science ®Google Scholar
• McDonaldVMHigginsIWoodLGGibsonPGMultidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense?Thorax201368769169423503624
   PubMed Web of Science ®Google Scholar
• MiravitllesMSoler-CatalunaJJCalleMSorianoJBTreatment of COPD by clinical phenotypes: putting old evidence into clinical practiceEur Respir J20134161252125623060631
   PubMed Web of Science ®Google Scholar
• HurstJRVestboJAnzuetoAEvaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) InvestigatorsSusceptibility to exacerbation in chronic obstructive pulmonary diseaseN Engl J Med2010363121128113820843247
   PubMed Web of Science ®Google Scholar
• SuissaSArielAThe FULFIL trialAm J Respir Crit Care Med20181974542
   Web of Science ®Google Scholar
• LipsonDABarnacleHBirkRReply to Suissa and Ariel: the FULFIL trialAm J Respir Crit Care Med20181974542543
   Web of Science ®Google Scholar
• SuissaSDell’AnielloSErnstPLong-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortalityThorax2012671195796322684094
   PubMed Web of Science ®Google Scholar
• WedzichaJACalverleyPMSeemungalTAINSPIRE InvestigatorsThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med20081771192617916806
   PubMed Web of Science ®Google Scholar
• MartinezFJVestboJAndersonJASUMMIT InvestigatorsEffect of fluticasone furoate and vilanterol on exacerbations of chronic obstructive pulmonary disease in patients with moderate airflow obstructionAm J Respir Crit Care Med2017195788188827767328
   PubMed Web of Science ®Google Scholar
• BeehKMDeromEEchave-SustaetaJThe lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study)Int J Chron Obstruct Pulmon Dis20161119320526893551
   PubMed Web of Science ®Google Scholar
• DonohueJFWorsleySZhuCQHardakerLChurchAImprovements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbationsRespir Med2015109787088126006754
   PubMed Web of Science ®Google Scholar
• VogelmeierCPaggiaroPLDorcaJEfficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD studyEur Respir J20164841030103927492833
   PubMed Web of Science ®Google Scholar
• WedzichaJADecramerMFickerJHAnalysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyLancet Respir Med20131319920924429126
   PubMed Web of Science ®Google Scholar
• RodrigoGJPriceDAnzuetoALABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysisInt J Chron Obstruct Pulmon Dis20171290792228360514
   PubMed Web of Science ®Google Scholar
• HoritaNGotoAShibataYLong-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD)Cochrane Database Syst Rev20172CD01206628185242
   PubMed Web of Science ®Google Scholar
• BeehKMBurgelPRFranssenFMEHow do dual long-acting bronchodilators prevent exacerbations of chronic obstructive pulmonary disease?Am J Respir Crit Care Med2017196213914927922741
   PubMed Web of Science ®Google Scholar
• VogelmeierCFBatemanEDPallanteJEfficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group studyLancet Respir Med201311516024321804
   PubMed Web of Science ®Google Scholar
• ZhongNWangCZhouXLANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPDInt J Chron Obstruct Pulmon Dis2015101015102626082625
   PubMed Web of Science ®Google Scholar